- Termination of Registration of a Class of Security under Section 12(g) (15-12G)
20 March 2009 - 3:45AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE
OF TERMINATION OF REGISTRATION UNDER SECTION 12(g)
OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER
SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number: 0-24241
PANACOS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
134 Coolidge Avenue
Watertown, Massachusetts 02472
(Address of Principal Executive Offices)
(617) 926-1551
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Common Stock, $0.01 Par Value
(Title of each
class of securities covered by this Form)
None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
|
|
|
|
|
|
|
Rule 12g-4(a)(1)
|
|
x
|
|
|
|
Rule 12g-4(a)(2)
|
|
¨
|
|
|
|
Rule 12h-3(b)(1)(i)
|
|
x
|
|
|
|
Rule 12h-3(b)(1)(ii)
|
|
¨
|
|
|
|
Rule 15d-6
|
|
¨
|
|
|
Approximate number of holders of record as of the certification or notice date: 140
Pursuant to the requirements of the Securities Exchange Act of 1934, Panacos Pharmaceuticals, Inc. has
caused this certification and notice to be signed on its behalf by the undersigned duly authorized person.
|
|
|
|
|
|
|
|
|
|
|
Date: March 19, 2009
|
|
By:
|
|
/s/ Alan W. Dunton, M.D.
|
|
|
|
|
|
Alan W. Dunton, M.D.
President and Chief Executive
Officer
|
Panacos Pharmaceuticals (CE) (USOTC:PANC)
Historical Stock Chart
From Dec 2024 to Jan 2025
Panacos Pharmaceuticals (CE) (USOTC:PANC)
Historical Stock Chart
From Jan 2024 to Jan 2025
